Erratum: Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia

No authors listed

Published Erratum

No authors listed. Saudi J Med Med Sci. 2021 May-Aug.

. 2021 May-Aug;9(2):199.

doi: 10.4103/1658-631X.315143.

Abstract

[This corrects the article on p. 16 in vol. 9, PMID: 33519339.].

Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia.
AlShehry N, Zaidi SZA, AlAskar A, Al Odayani A, Alotaibi JM, AlSagheir A, Al-Eyadhy A, Balelah S, Salam A, Zaidi ARZ, Alawami D, Alshahrani MS, AlMozain N, Abulhamayel YM, Al Qunfoidi R, Alfaraj M, Qushmaq N, Alansari R, Dayel A, Elgohary G, Al Bahrani A, Nabhan Abdelhameed AA, AlZahrani HA, Alturkistani H, AlShehry N, Albalawi MA, Elalfy I, Alhumaidan H, Al-Hashmi H; KSA COVID-19 Convalescent Plasma Study Group. AlShehry N, et al. Saudi J Med Med Sci. 2021 Jan-Apr;9(1):16-23. doi: 10.4103/sjmms.sjmms_731_20. Epub 2020 Dec 26. Saudi J Med Med Sci. 2021. PMID: 33519339 Free PMC article.

1. AlShehry N, Zaidi SZ, AlAskar A, Al Odayani A, Alotaibi JM, AlSagheir A, et al. Safety and efficacy of convalescent plasma for severe COVID-19: Interim report of a multicenter phase II study from Saudi Arabia. Saudi J Med Med Sci. 2021;9:16–23. - PMC - PubMed